Concept Life Sciences is involved in drug discovery and development, providing services from early-stage research to IND enabling, utilizing experienced scientists.

Concept Life Sciences

Concept Life Sciences | 3,940 followers on LinkedIn. A knowledge-based, science-led and customer-focused contract research and manufacturing organisation. | Concept Life Sciences is a knowledge-based, science-led and customer-focused contract research and manufacturing organisation with world-leading expertise in the pharmaceutical, biotech and agrochemical industries.  

We are based across 5 sites in the UK delivering discovery research as well as GMP, GLP and GCP-regulated work. 

Whether it is delivering whole programs of research or bespoke studies we deliver a collaborative client-centred approach.

Partner Healthcare & Lifesciences Limerston Capital

Jane Grewar

Global Sales & Marketing Executive and team builder with extensive network in CRO, proteomics and CDMO services

Kenna Harris

Garry Boyd

Chemistry Services Director and Site Head

Mark Betson

If you missed our webinar hosted by Dr Thomas Pesnot (FRSC) with keynote speaker Dr Rob Riley on the ADMET Toolkit for clinical pharmacokinetics, you can download it on demand using the link below 👇. This webinar covers critical aspects of drug discovery, including the importance of ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity), key challenges, and strategies for designing effective screening cascades. Download it today : https://shorturl.at/gYPVF

Nearly time to attend SITC! If you need a rapid and robust way to asses the impact of your immunotherapy, our experts can help you select the right test system for your evaluations. Set up a meeting with our Associate Director of immunology Justyna Rzepecka at SITC https://lnkd.in/eHz62RzZ or arrange a call for after the meeting. Whilst there don't miss out on her poster presentation. Stay tuned for more details. #SITC2024 #event #posterpresentation #immunology #immunotherapy #CRO #UKCRO

Concept Life Sciences completes acquisition of Charnwood Discovery #CRO Limerston Capital Ben Cliff Lee Patterson https://lnkd.in/eYfAuS-D

Investors in Healthcare

We are pleased to announce the acquisition of Charnwood Discovery , a leading provider of drug discovery research. This milestone strengthens our position as a market leader in the life sciences sector, allowing us to offer an even broader range of services across drug discovery, development, and manufacturing, across small molecules, biologics and other novel therapeutic modalities. With our combined expertise, we look forward to driving innovation and making a significant impact on the biotech and pharmaceutical industries. Read the full press release here : https://shorturl.at/7a4AB #LifeSciences #DrugDiscovery #Innovation #Pharmaceuticals #Biotech #Growth

Have you booked your meeting with Li Luo and Jamie Stokes yet? Whether you’re attending Oxford Global #DiscoveryUS2024 or are local to the Boston area our team would be delighted to discuss how we can #accelerate your #drugdiscovery from #concept to #clinic

We are thrilled to announce that our newly expanded state-of-the-art labs featuring cutting-edge automation for ADMET screening are now complete! This strategic investment marks a significant enhancement in our ADMET & DMPK capabilities to support pharmaceutical research. What this means for our customers: · Expanded capacity and even faster turnaround times for your projects. · Advanced automation for higher throughput and accuracy in ADMET profiling. Our commitment to innovation and excellence in drug discovery has never been stronger. Stay tuned for more updates and success stories from our expanded labs. #Biotech #Pharmaceuticals #DrugDiscovery #ADME #DMPK #ADMET #Innovation #LabExpansion #Automation #LifeSciences #Investment

Some interesting reading on #ADC from Jamie Stokes this morning! Our experts can support your #warhead and #linker design, #synthesis , #bioconjugation and #biological testing of your ADC To learn more follow these links https://lnkd.in/eVXi9esU https://lnkd.in/e5hDcenU #DAR #Bioconjugation #cytotoxics #antibodies #linkers #synthesis

Why use HT parallel screening for API production? One of our clients needed a 300 g synthesis of an API for a toxicology study. The existing synthetic route had previously been achieved on 50 g scale but improvements to the key Suzuki coupling step were required to enable scale up. Use of our high-throughput parallel screening workflow uncovered a ligand that switched off the protodeborylation pathway reducing the amount of boronic acid required to one equivalent and which was accompanied by an increase in reaction yield. Within four weeks of development, the Suzuki reaction was successfully run on a 500 g scale and the product was rapidly converted to > 300 g of API and delivered to our client for their tox study. Most early-stage routes to an API are developed at speed for target screening. Consequently, many of these routes are developed to prepare milligrams of API and are therefore ill-suited to deliver enough material for IND-enabling studies. We can support the development of fit-for-purpose synthetic routes by identifying the problematic transformations and providing bespoke solutions. If you have a challenge in rapidly delivering sufficient API, we have a solution for you. Download our flyer below 👇 to find out more or alternatively email us on : cls-info@conceptlifesciences.com #Concept2Clinic #MedicinalChemistry #DrugDiscovery #ProcessDevelopment #CRO #GMP

Last day of EORTC - European Organisation for Research and Treatment of Cancer today!

It's Day 2 of the American Association of Pharmaceutical Scientists (AAPS) | @aapscomms Have you had a chance to stop by our booth yet? We’re at #2530. Our map design has been gaining a lot of attention recently, so don't miss the opportunity to meet Kenna Harris or Li Luo to grab a notebook or screen cloth. These will help you keep track of the key steps from Concept to Clinic. Also, make sure to connect with our colleague Felix Beltran from Astoriom while you're there. #AAPS #Event #ConcepttoClinic #CRO #UKCRO

Metric
Company Name	Concept Life Sciences
Symbol
MSH ID	COM:CONCEPTLIFESCIENCES
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	GB
Stage
Employee Count
Website	conceptlifesciences.com
LinkedIn	concept-life-sciences-limited
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CONC

COM:CONCEPTLIFESCIENCES

Concept Life Sciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue